BILLING GUIDE FOR REMICADE® (infliximab) AND Infliximab

SELECTED IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal side effects have been reported with REMICADE® and Infliximab. Infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens (eg, TB, histoplasmosis) have been reported. Lymphoma, including cases of fatal hepatosplenic T-cell lymphoma (HSTCL), and other malignancies have been reported, including in children and young adult patients. Due to the risk of HSTCL, mostly reported in Crohn’s disease and ulcerative colitis, assess the risk/benefit, especially if the patient is male and is receiving azathioprine or 6-mercaptopurine treatment. REMICADE® and Infliximab are contraindicated at doses >5 mg/kg in patients with moderate or severe heart failure and in patients with severe hypersensitivity reactions to REMICADE® and Infliximab. Other serious side effects reported include melanoma, Merkel cell carcinoma, invasive cervical cancer, hepatitis B reactivation, hepatotoxicity, hematological events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurological events, and lupus-like syndrome. Please see related and other Important Safety Information on pages 22-23 for REMICADE® and Infliximab.
Janssen Biotech, Inc. is committed to providing reimbursement information for REMICADE® and Infliximab to you. This Billing Guide has been developed to provide you with information regarding:

- Essential Coding Considerations
- Sample Claims Forms
- Important Product Information
- Reimbursement Support Resources

Information about REMICADE® and Infliximab access and reimbursement support resources is available through Janssen CarePath. Please call 877-CarePath (877-227-3728) to speak with a Janssen CarePath Care Coordinator about reimbursement-related questions or concerns.

Disclaimer

Third-party reimbursement is affected by many factors. This document and the information and assistance provided by Janssen CarePath are presented for informational purposes only. They do not constitute reimbursement or legal advice. Janssen CarePath does not promise or guarantee coverage, levels of reimbursement, or payment.

Similarly, all CPT®* and HCPCS codes are supplied for informational purposes only and represent no statement, promise, or guarantee, expressed or implied, by Janssen or its third-party service providers that these codes will be appropriate or that reimbursement will be made. The fact that a drug, device, procedure, or service is assigned an HCPCS code and a payment rate does not imply coverage by the Medicare program, but indicates only how the product, procedure, or service may be paid if covered by the Medicare program.

Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. Accordingly, the information may not be current or comprehensive. Janssen and its third-party service providers strongly recommend you consult your payer for its most current coverage, reimbursement, and coding policies. Janssen and its third-party service providers make no representations or warranties, expressed or implied, as to the accuracy of the information provided. In no event shall the third-party service providers or Janssen, or their employees or agents, be liable for any damages resulting from or relating to any information provided by, or accessed to or through, Janssen CarePath. All HCPs and other users of this information agree that they accept responsibility for the use of this program.


Please see Important Safety Information for REMICADE® and Infliximab on pages 22-23.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTRODUCTION</td>
<td>2</td>
</tr>
<tr>
<td>UNDERSTANDING UNBRANDED BIOLOGICS</td>
<td>4</td>
</tr>
<tr>
<td>INDICATIONS</td>
<td>5</td>
</tr>
<tr>
<td>DOSING AND ADMINISTRATION</td>
<td>6</td>
</tr>
<tr>
<td>CODING FOR REMICADE® AND Infliximab</td>
<td>8</td>
</tr>
<tr>
<td>ICD-10-CM Diagnosis Codes</td>
<td>8</td>
</tr>
<tr>
<td>National Drug Code (NDC)</td>
<td>9</td>
</tr>
<tr>
<td>HCPCS Level II Codes</td>
<td>10</td>
</tr>
<tr>
<td>CODING FOR DRUG ADMINISTRATION</td>
<td>11</td>
</tr>
<tr>
<td>OTHER CODING CONSIDERATIONS</td>
<td>12</td>
</tr>
<tr>
<td>Place of Service Codes</td>
<td>12</td>
</tr>
<tr>
<td>Revenue Codes</td>
<td>12</td>
</tr>
<tr>
<td>HCPCS and CPT® Modifiers</td>
<td>13</td>
</tr>
<tr>
<td>Same-Day Evaluation and Management Services</td>
<td>14</td>
</tr>
<tr>
<td>CMS Discarded Drug Policy</td>
<td>14</td>
</tr>
<tr>
<td>Drugs Supplied at No Cost to the Provider</td>
<td>14</td>
</tr>
<tr>
<td>SAMPLE CLAIMS FORMS</td>
<td>15</td>
</tr>
<tr>
<td>Physician Office Claims (CMS-1500)</td>
<td>15</td>
</tr>
<tr>
<td>Hospital Outpatient Claims (CMS-1450)</td>
<td>15</td>
</tr>
<tr>
<td>COVERAGE CONSIDERATIONS</td>
<td>20</td>
</tr>
<tr>
<td>JANSSEN CAREPATH</td>
<td>21 &amp; 24</td>
</tr>
<tr>
<td>IMPORTANT SAFETY INFORMATION</td>
<td>22</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>24</td>
</tr>
</tbody>
</table>
REMICADE® (infliximab) AND Infliximab

Infliximab IS AN UNBRANDED BIOLOGIC FROM THE MAKERS OF REMICADE®

Janssen's unbranded Infliximab is REMICADE® without the brand name1-3

Produced from the same cell line and at the same manufacturing sites as REMICADE®
Approved for all the same indications as REMICADE® with the same safety and efficacy profile
Available in the same strength, same dosage form, and same route of administration as REMICADE®
Offering the same affordability and patient support programs as REMICADE®

UNDERSTANDING UNBRANDED BIOLOGICS
An unbranded biologic is NOT a biosimilar4

BRAND-NAME BIOLOGIC5
Approved based on a full complement of safety and effectiveness data
Produced through biotechnology in a living system (ie, a “cell line”)

UNBRANDED BIOLOGIC4
The same as the brand-name biologic
Produced using the same cell line as the brand-name biologic

BIOSIMILAR5,6
Highly similar to brand-name biologic* with no clinically meaningful differences
Produced using a different cell line

**“Brand-name biologic” refers to the reference biologic.

SELECTED IMPORTANT SAFETY INFORMATION
Serious and sometimes fatal side effects have been reported with REMICADE® and Infliximab. Infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens (eg, TB, histoplasmosis) have been reported. Lymphoma, including cases of fatal hepatosplenic T-cell lymphoma (HSTCL), and other malignancies have been reported, including in children and young adult patients. Due to the risk of HSTCL, mostly reported in Crohn’s disease and ulcerative colitis, assess the risk/benefit, especially if the patient is male and is receiving azathioprine or 6-mercaptopurine treatment. REMICADE® and Infliximab are contraindicated at doses >5 mg/kg in patients with moderate or severe heart failure and in patients with severe hypersensitivity reactions to REMICADE® and Infliximab. Other serious side effects reported include melanoma, Merkel cell carcinoma, invasive cervical cancer, hepatitis B reactivation, hepatotoxicity, hematological events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurological events, and lupus-like syndrome. Please see related and other Important Safety Information on pages 22-23 for REMICADE® and Infliximab.

Back to Table of Contents.
INDICATIONS

Crohn's Disease
REMICADE® and Infliximab are indicated for:
- reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.
- reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.

Pediatric Crohn’s Disease
REMICADE® and Infliximab are indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy.

Ulcerative Colitis
REMICADE® and Infliximab are indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Pediatric Ulcerative Colitis
REMICADE® and Infliximab are indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy.

Rheumatoid Arthritis
REMICADE® or Infliximab, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA).

Ankylosing Spondylitis
REMICADE® and Infliximab are indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).

Psoriatic Arthritis
REMICADE® and Infliximab are indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).

Plaque Psoriasis
REMICADE® and Infliximab are indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. REMICADE® or Infliximab should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

SELECTED IMPORTANT SAFETY INFORMATION
Serious and sometimes fatal side effects have been reported with REMICADE® and Infliximab. Infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens (eg, TB, histoplasmosis) have been reported. Lymphoma, including cases of fatal hepatosplenic T-cell lymphoma (HSTCL), and other malignancies have been reported, including in children and young adult patients. Due to the risk of HSTCL, mostly reported in Crohn's disease and ulcerative colitis, assess the risk/benefit, especially if the patient is male and is receiving azathioprine or 6-mercaptopurine treatment. REMICADE® and Infliximab are contraindicated at doses >5 mg/kg in patients with moderate or severe heart failure and in patients with severe hypersensitivity reactions to REMICADE® and Infliximab. Other serious side effects reported include melanoma, Merkel cell carcinoma, invasive cervical cancer, hepatitis B reactivation, hepatotoxicity, hematological events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurological events, and lupus-like syndrome. Please see related and other Important Safety Information on pages 22-23 for REMICADE® and Infliximab.
DOSING AND ADMINISTRATION\textsuperscript{1,2}

REMICADE\textsuperscript{®} and Infliximab dosing is weight based and indication specific. Infusions are administered every 8 weeks (or 6 weeks for those with active Ankylosing Spondylitis) after 3 induction doses. Both induction and maintenance doses are administered by intravenous infusion over a period of not less than 2 hours.

**Table 1a. Recommended Dosage and Intervals for REMICADE\textsuperscript{®} and Infliximab in Adult Patients\textsuperscript{1,2}**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Induction</th>
<th>Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderately to Severely Active Crohn's Disease\textsuperscript{*}</td>
<td>5 mg/kg 0, 2, and 6 weeks</td>
<td>5 mg/kg\textsuperscript{1} every 8 weeks</td>
</tr>
<tr>
<td>*Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinuing REMICADE\textsuperscript{®} or Infliximab in these patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderately to Severely Active Ulcerative Colitis</td>
<td>5 mg/kg 0, 2, and 6 weeks</td>
<td>3 mg/kg\textsuperscript{2} every 8 weeks</td>
</tr>
<tr>
<td>Moderately to Severely Active Rheumatoid Arthritis\textsuperscript{1}</td>
<td>3 mg/kg 0, 2, and 6 weeks</td>
<td>3 mg/kg\textsuperscript{3} every 8 weeks</td>
</tr>
<tr>
<td>*In conjunction with methotrexate.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active Ankylosing Spondylitis</td>
<td>5 mg/kg 0, 2, and 6 weeks</td>
<td>5 mg/kg every 6 weeks</td>
</tr>
<tr>
<td>Active Psoriatic Arthritis\textsuperscript{2}</td>
<td>5 mg/kg 0, 2, and 6 weeks</td>
<td>5 mg/kg every 8 weeks</td>
</tr>
<tr>
<td>*Can be used with or without methotrexate.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Severe Plaque Psoriasis</td>
<td>5 mg/kg 0, 2, and 6 weeks</td>
<td>5 mg/kg every 8 weeks</td>
</tr>
</tbody>
</table>

**Table 1b. Recommended Dosage and Intervals for REMICADE\textsuperscript{®} and Infliximab in Pediatric Patients (≥6 Years)\textsuperscript{1,2}**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Induction</th>
<th>Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderately to Severely Active Crohn's Disease</td>
<td>5 mg/kg 0, 2, and 6 weeks</td>
<td>5 mg/kg every 8 weeks</td>
</tr>
<tr>
<td>Moderately to Severely Active Ulcerative Colitis</td>
<td>5 mg/kg 0, 2, and 6 weeks</td>
<td>5 mg/kg every 8 weeks</td>
</tr>
</tbody>
</table>

**SELECTED IMPORTANT SAFETY INFORMATION**

Serious and sometimes fatal side effects have been reported with REMICADE\textsuperscript{®} and Infliximab. Infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens (eg, TB, histoplasmosis) have been reported. Lymphoma, including cases of fatal hepatosplenic T-cell lymphoma (HSTCL), and other malignancies have been reported, including in children and young adult patients. Due to the risk of HSTCL, mostly reported in Crohn's disease and ulcerative colitis, assess the risk/benefit, especially if the patient is male and is receiving azathioprine or 6-mercaptopurine treatment. REMICADE\textsuperscript{®} and Infliximab are contraindicated at doses >5 mg/kg in patients with moderate or severe heart failure and in patients with severe hypersensitivity reactions to REMICADE\textsuperscript{®} and Infliximab. Other serious side effects reported include melanoma, Merkel cell carcinoma, invasive cervical cancer, hepatitis B reactivation, hepatotoxicity, hematological events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurological events, and lupus-like syndrome. Please see related and other Important Safety Information on pages 22-23 for REMICADE\textsuperscript{®} and Infliximab.

Back to Table of Contents.
Preparation and Administration of REMICADE® or Infliximab for IV Infusion

REMICADE® and Infliximab are supplied in a carton containing one single-dose vial. REMICADE® and Infliximab are intended for use under the guidance and supervision of a healthcare provider. The reconstituted infusion solution should be prepared by a trained medical professional using aseptic technique. REMICADE® or Infliximab are administered by intravenous infusion over a period of not less than 2 hours.

1. Calculate the dose, total volume of reconstituted solution required, and the number of vials needed based on the patient’s weight and indication.

2. Reconstitute each 100-mg vial with 10 mL of Sterile Water for Injection, USP, to obtain a concentration of 10 mg/mL using a syringe equipped with a 21-gauge or smaller needle as follows:
   - Remove the flip-top from the vial and wipe the top with an alcohol swab. Insert the syringe needle into the vial through the center of the rubber stopper and direct the stream of Sterile Water for Injection, USP, to the glass wall of the vial.
   - Gently swirl the solution by rotating the vial to dissolve the lyophilized powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE. Foaming of the solution on reconstitution is not unusual.
   - Allow the reconstituted solution to stand for 5 minutes. The solution should be colorless to light yellow and opalescent, and the solution may develop a few translucent particles as infliximab is a protein. Do not use if the lyophilized cake has not fully dissolved or if opaque particles, discoloration, or other foreign particles are present.

3. Dilute the total volume of the reconstituted solution to 250-mL* with sterile 0.9% Sodium Chloride Injection, USP, by withdrawing a volume equal to the volume of reconstituted solution from the 0.9% Sodium Chloride Injection, USP, 250-mL bottle or bag. Do not dilute the reconstituted solution with any other diluent. Slowly add the total volume of reconstituted solution to the 250-mL infusion bottle or bag. Gently invert the bag to mix the solution. The resulting infusion concentration should range between 0.4 mg/mL and 4 mg/mL.

4. The infusion should begin within 3 hours of reconstitution and dilution. The infusion must be administered intravenously for at least 2 hours and must use an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 1.2-μm or less). REMICADE® and Infliximab vials do not contain preservatives. Therefore, any unused portion of the infusion solution should be discarded and not be stored for reuse.

5. The diluted solution should not be infused concomitantly in the same intravenous line with other agents.

6. Parenteral drug products should be inspected visually before and after reconstitution for particulate matter and discoloration prior to administration, whenever solution and container permit. If visibly opaque particles, discoloration or other foreign particulates are observed, the solution should not be used.

Please refer to the Dosage and Administration section of the full Prescribing Information for REMICADE® or full Prescribing Information for Infliximab for complete information on how to prepare and administer REMICADE® or Infliximab.

*For volumes greater than 250-mL, either use a larger infusion bag or multiple 250-mL infusion bags to ensure that the concentration of the infusion solution does not exceed 4 mg/mL.

SELECTED IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal side effects have been reported with REMICADE® and Infliximab. Infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens (eg, TB, histoplasmosis) have been reported. Lymphoma, including cases of fatal hepatosplenic T-cell lymphoma (HSTCL), and other malignancies have been reported, including in children and young adult patients. Due to the risk of HSTCL, mostly reported in Crohn’s disease and ulcerative colitis, assess the risk/benefit, especially if the patient is male and is receiving azathioprine or 6-mercaptopurine treatment. REMICADE® and Infliximab are contraindicated at doses >5 mg/kg in patients with moderate or severe heart failure and in patients with severe hypersensitivity reactions to REMICADE® and Infliximab. Other serious side effects reported include melanoma, Merkel cell carcinoma, invasive cervical cancer, hepatitis B reactivation, hepatotoxicity, hematological events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurological events, and lupus-like syndrome. Please see related and other Important Safety Information on pages 22-23 for REMICADE® and Infliximab.
**ICD-10-CM Diagnosis Codes**

ICD-10-CM diagnosis codes use 3 to 7 alpha and numeric characters to achieve the greatest level of specificity. Codes with 3 characters are included in ICD-10-CM as the heading of a category of codes that may be further subdivided by use of additional characters to provide greater detail. A 3-character code is to be used only if it is not further subdivided. A code is invalid if it has not been coded to the full number of characters required for that code, including the 7th character, if applicable.7

*These codes are not intended to be promotional or to encourage or suggest a use of drug that is inconsistent with US Food and Drug Administration-approved use. The codes provided are not exhaustive and additional codes may apply. Listed codes may require a higher level of specificity when reporting for individual patients.

<table>
<thead>
<tr>
<th>Table 2. ICD-10-CM Codes(^a) for Consideration*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crohn's Disease</strong></td>
</tr>
<tr>
<td>K50.00 Crohn's disease of small intestine without complications</td>
</tr>
<tr>
<td>K50.10 Crohn's disease of large intestine without complications</td>
</tr>
<tr>
<td>K50.80 Crohn's disease of both small and large intestine without complications</td>
</tr>
<tr>
<td>K50.90 Crohn's disease, unspecified, without complications</td>
</tr>
<tr>
<td><strong>Fistula (Use in Addition to Codes for Crohn's Disease)</strong></td>
</tr>
<tr>
<td>K60.3 Anal fistula</td>
</tr>
<tr>
<td>K60.4 Rectal fistula</td>
</tr>
<tr>
<td><strong>Ulcerative Colitis</strong></td>
</tr>
<tr>
<td>K51.80 Other ulcerative colitis without complications</td>
</tr>
<tr>
<td>K51.20 Ulcerative (chronic) proctitis without complications</td>
</tr>
<tr>
<td>K51.30 Ulcerative (chronic) rectosigmoiditis without complications</td>
</tr>
<tr>
<td>K51.50 Left-sided colitis without complications</td>
</tr>
<tr>
<td>K51.00 Ulcerative (chronic) pancolitis without complications</td>
</tr>
<tr>
<td>K51.90 Ulcerative colitis, unspecified, without complications</td>
</tr>
<tr>
<td><strong>Rheumatoid Arthritis</strong></td>
</tr>
<tr>
<td>M06.00 Rheumatoid arthritis w/o rheumatoid factor, unspecified site</td>
</tr>
<tr>
<td>M05.60 Rheumatoid arthritis of unspecified site with involvement of other organs and systems</td>
</tr>
<tr>
<td>M05.70 Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement</td>
</tr>
<tr>
<td><strong>Ankylosing Spondylitis</strong></td>
</tr>
<tr>
<td>M45.9 Ankylosing spondylitis of unspecified sites in spine</td>
</tr>
<tr>
<td><strong>Psoriatic Arthritis</strong></td>
</tr>
<tr>
<td>L40.50 Arthropathic psoriasis, unspecified</td>
</tr>
<tr>
<td><strong>Plaque Psoriasis</strong></td>
</tr>
<tr>
<td>L40.0 Psoriasis vulgaris</td>
</tr>
</tbody>
</table>

*These codes are not intended to be promotional or to encourage or suggest a use of drug that is inconsistent with US Food and Drug Administration-approved use. The codes provided are not exhaustive and additional codes may apply. Listed codes may require a higher level of specificity when reporting for individual patients.

Please see Important Safety Information for REMICADE\(^a\) and Infliximab on pages 22 and 23.

Back to Table of Contents.
CODING (cont’d)

National Drug Code (NDC)
The National Drug Code (NDC) is a unique number that identifies a drug's labeler, product, and trade package size. The NDC has typically been reserved for pharmacy billing, including drugs provided for home infusion. However, Medicaid fee-for-service programs, Medicare crossover claims for dual-eligible beneficiaries and some private payers now also require the NDC for billing instead of, or in addition to, the HCPCS code, for physician claims and those of other service providers. Although the FDA uses a 10-digit format when registering NDCs, payer requirements regarding the use of the 10- or 11-digit NDC may vary. Electronic data exchange generally requires use of the 11-digit NDC. To convert the 10-digit format to the 11-digit format, insert a leading zero into the middle sequence, as illustrated below. In some cases, you may be required to include the NDC number on a claim form.

NDC Units
The NDC unit of measure is determined by how the drug is supplied. In the outpatient setting, UN (unit) applies to drugs supplied in a vial in powder form, requiring reconstitution before administration, and mL (milliliters) applies to drugs supplied in vials in liquid form. NDC units dispensed are based on the packaging and numeric quantity administered to the patient. Here is an example for a 400-mg dose:

<table>
<thead>
<tr>
<th>Dose to Be Billed</th>
<th>NDC (11-digit)</th>
<th>Packaging</th>
<th>NDC Unit of Measure</th>
<th>NDC Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMICADE®</td>
<td>400 mg</td>
<td>57894-0030-01</td>
<td>100-mg vial (powder)</td>
<td>UN</td>
</tr>
<tr>
<td>Infliximab</td>
<td>400 mg</td>
<td>57894-0160-01</td>
<td>100-mg vial (powder)</td>
<td>UN</td>
</tr>
</tbody>
</table>

In this example the drug is supplied in 100-mg vials, in powder form for reconstitution. The NDC is specific to the packaging, thus one 100-mg vial equals 1 NDC unit. The total dose to be billed is 400 mg (400 divided by 100), or 4 NDC units. The drug is packaged in powder form so the unit of measure is “UN.” Accurate NDC coding typically requires the following components:

• Reporting the NDC with 11 digits in a 5-4-2 configuration; this may require converting a 10-digit NDC to an 11-digit NDC
• Reporting the correct NDC unit of measure (ie, UN, mL)
• Reporting the number of NDC units dispensed
• Reporting the qualifier, N4, in front of the NDC

For REMICADE®, using the same 400-mg example, this format would appear as: N457894003001 UN4

For Infliximab, using the same 400-mg example, this format would appear as: N457894016001 UN4

Payer requirements for NDC use and format may vary. Please contact your payers for specific coding policies and more information on correct billing and claims submission. For additional support, you may visit JanssenCarePath.com/hcp/Remicade or contact Janssen CarePath at 877-CarePath (877-227-3728).

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
Healthcare Common Procedure Code System (HCPCS) Level II Codes (eg, J codes)

Drugs are typically reported using product-specific HCPCS codes (eg, J codes) assigned by the Centers for Medicare & Medicaid Services (CMS). HCPCS units are determined by the specific HCPCS descriptor. The descriptor is not necessarily the same as the package or therapeutic dose, so the dose must be converted to billable HCPCS units to accurately complete a claim. The HCPCS code for REMICADE® and Infliximab is:

**J1745 - Injection, infliximab, excludes biosimilar, 10 mg**

Each 100-mg vial of drug represents 10 units of J1745, thus each 10-mg dose of REMICADE® or Infliximab equals one billing unit, or 1/10th of a vial. When coding for J1745, report the total number of 10-mg increments administered. Table 5 illustrates the correlation between vials, milligrams, and billing units for REMICADE® and Infliximab.

<table>
<thead>
<tr>
<th>Number of 100-mg Vials</th>
<th>Total Milligrams (mg)</th>
<th>Number of Billing Units Based on J1745 (10 mg Per Unit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>100</td>
<td>10</td>
</tr>
<tr>
<td>2</td>
<td>200</td>
<td>20</td>
</tr>
<tr>
<td>3</td>
<td>300</td>
<td>30</td>
</tr>
<tr>
<td>4</td>
<td>400</td>
<td>40</td>
</tr>
</tbody>
</table>

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
CODING FOR DRUG ADMINISTRATION

Coding for Drug Administration Services
This section reviews general coding guidelines for drug administration services coded by physician offices using the CMS-1500 claim form and by hospital outpatient departments using the CMS-1450 (UB-04) claim form. Please note that HCPs are responsible for selecting appropriate codes for any particular claim based on the patient’s condition, the items and services that are furnished, and any specific payer requirements. It is advisable to contact your local payer with regard to local payment policies.

Codes for Drug Administration
Drug administration services are reported on claims forms in both the physician office (CMS-1500) and hospital outpatient (CMS-1450) sites of care using the CPT® coding system. The CPT® codes most commonly associated with the administration of REMICADE® or Infliximab are:

- **96413** - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug, and
- **96415** - Each additional hour (Use 96415 in conjunction with 96413; report 96415 for infusion intervals of greater than 30 minutes beyond 1-hour increments.)

These codes, often referred to as “complex” codes, apply to the parenteral administration of chemotherapy and also antineoplastic agents provided for treatment of noncancer diagnoses, or to substances such as certain monoclonal antibodies and other biologic response modifiers. Complex drug administration services also require special considerations to prepare, dose, or dispose and typically entail professional skill and patient monitoring significantly beyond that required for therapeutic infusions.

Alternatively, some payers may require the use of these CPT® codes:

- **96365** - Intravenous infusion for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour, and
- **96366** - Each additional hour (List separately in addition to code for primary procedure; report 96366 for infusion intervals of greater than 30 minutes beyond 1-hour increments.)

These codes, often referred to as “therapeutic” codes, typically require special considerations to prepare, dose, or dispose of the drug/biologic and necessitate special training and competency for the staff who administer it. These services generally require periodic patient assessment during and/or after the procedure.

Payer policies for codes used to describe infusion services may vary. Consult your payers for policies regarding use of 96413 and 96415 or 96365 and 96366. For information and assistance, please contact Janssen CarePath at 877-CarePath (877-227-3728) or visit JanssenCarePath.com/hcp/Remicade.

Partial Additional Hours of Infusion Time
CMS has a policy for reporting the add-on infusion codes when less than a full hour of service is provided. Providers may report the add-on infusion code for “each additional hour” only if the infusion interval is greater than 30 minutes beyond the 1-hour increment. For example, if the patient receives an infusion of a single drug that lasts 2 hours, the provider would report the “initial” code up to 1 hour and the add-on code for the additional 60 minutes. If the incremental amount of infusion time is 30 minutes or less, the time is not to be billed separately. Note that some payers may require reporting the actual number of minutes on the claim.

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
OTHER CODING CONSIDERATIONS

Place of Service Codes

The Place of Service (POS) code set provides setting information necessary to appropriately pay professional service claims. The place of service is the location of the provider's face-to-face encounter with the beneficiary. POS codes are required on all claims for professional services (billed on the CMS-1500). Under the Physician Fee Schedule (PFS), some procedures have separate rates for professional services when provided in facility and nonfacility settings; therefore, it is important to accurately designate the POS to ensure appropriate payment. The physician practice location is considered “nonfacility” (NF), allowing for the practice expenses to be included in the payment under the PFS. When professional services are performed in a facility (eg, hospital outpatient department), the practice does not incur the same expense (eg, overhead, staff, equipment and supplies), thus payment under the PFS is generally lower for facility-based services than for NF services.

The physician practice setting is indicated with POS code 11. To differentiate between on-campus and off-campus provider-based departments, CMS created a new POS code (POS 19) and revised the POS code description for outpatient hospital (POS 22). Professional services delivered in outpatient hospital settings must now specifically include the off-campus or on-campus POS on the claim form.

<table>
<thead>
<tr>
<th>POS Code</th>
<th>POS Name</th>
<th>POS Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Office</td>
<td>Location, other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, state or local public health clinic, or intermediate care facility (ICF), where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.</td>
</tr>
<tr>
<td>19</td>
<td>Off Campus – Outpatient Hospital</td>
<td>A portion of an off-campus hospital provider-based department that provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization. (Effective January 1, 2016)</td>
</tr>
<tr>
<td>22</td>
<td>On Campus – Outpatient Hospital</td>
<td>A portion of a hospital's main campus that provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization. (Description change effective January 1, 2016)</td>
</tr>
</tbody>
</table>

Revenue Codes

Many payers require use of American Hospital Association (AHA) revenue codes to bill for services provided in hospital outpatient departments. Revenue codes consist of a leading zero followed by three other digits and are used on claims forms to assign costs to broad categories of hospital revenue centers. Codes used for Medicare claims are available from Medicare contractors. The following revenue codes may be applicable to CMS-1450 claims for drugs and their administration:

- 0260 IV Therapy, General
- 0510 Clinic, General
- 0636 Pharmacy, drugs requiring detailed coding

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
OTHER CODING CONSIDERATIONS (cont’d)

HCPCS and CPT® Modifiers

Modifiers are used to report or indicate that a service or procedure has been altered by some specific circumstance but not changed in its definition or code. They provide additional information about a service or procedure and help to eliminate the appearance of duplicate billing and unbundling. This could include using modifiers to designate a specific site of service or to document an interrupted procedure, wasted product, same-day procedure, etc. Appropriately used, modifiers improve coding and reimbursement accuracy.

Table 7 summarizes modifiers that may be applicable to the provision of REMICADE® or Infliximab in physician offices and hospital outpatient departments.

<table>
<thead>
<tr>
<th>Modifier</th>
<th>Description</th>
<th>Indication and Placement</th>
<th>CMS-1500 (Item 24D)</th>
<th>CMS-1450 (Box 44)</th>
</tr>
</thead>
</table>
| **25**   | Significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified HCP on the same day of the procedure or other service[^11] | • Patient requires distinct E/M service in addition to the infusion procedure[^11]  
• Must be substantiated by documentation that supports the relevant criteria for the reported E/M code[^11]  
• Append the modifier to the appropriate E/M code[^11] | ✓ ✓ | |
| **JW**   | Drug amount discarded/not administered to any patient[^10]                  | • Applies only to the unused drug that is discarded after applicable dose has been administered from a single-use vial[^15]  
• Append the modifier to the drug code on a line separate from that reporting the administered dose[^15] | ✓ Required by Medicare | ✓ Required by Medicare |
| **PO**   | Excepted services provided at an off-campus, outpatient provider-based department of a hospital[^10] | • To be reported on each claim line for excepted services furnished in an off-campus, provider-based department of a hospital and billed on an institutional claim[^16] | N/A | ✓ Required by Medicare |
| **PN**   | Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital[^10] | • To be reported on each claim line for non-excepted services furnished in an off-campus provider-based department of a hospital and billed on an institutional claim[^16] | N/A | ✓ Required by Medicare |
| **JG**   | Drug or biological acquired with 340B Drug Pricing Program Discount[^10]    | • Must be reported by providers who are NOT excepted[^1] from the 340B payment policy[^16]  
• To be reported on the same claim line as the drug HCPCS code for all 340B acquired drugs[^16] | N/A | ✓ Required by Medicare |
| **TB**   | Drug or biological acquired with 340B Drug Pricing Program Discount, reported for informational purposes[^10] | • Must be reported by providers who ARE excepted[^1] from the 340B payment policy[^16]  
• To be reported on the same claim line as the drug HCPCS code for all 340B acquired drugs[^16] | N/A | ✓ Required by Medicare |

[^1]: Neither the PO nor the PN modifier is to be reported for dedicated emergency departments, remote locations or satellite facilities of a hospital, or a provider-based department that is “on campus.”[^14]

[^10]: The following provider types are excepted from the 340B payment policy: rural sole community hospitals, childrens’ hospitals, and Medicare Prospective Payment System (PPS)-exempt cancer hospitals.[^14]

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
OTHER CODING CONSIDERATIONS (cont’d)

Same-Day Evaluation and Management Services

It may be necessary to provide E/M services on the same day as a drug administration procedure. Depending on the payer, E/M services that are medically necessary, separate, distinct from the drug administration procedure, and documented appropriately are generally covered.

Please note that CMS has a specific policy regarding use of CPT® code 99211 (level 1 medical visit for an established patient) in the physician office. The policy states:

CPT® code 99211 cannot be paid if it is billed, with or without modifier 25, with a chemotherapy or nonchemotherapy drug administration code. 12

Thus, CPT® code 99211 cannot be paid on the same day as an office-based infusion of REMICADE® or Infliximab. If a therapeutic or complex drug administration service and a significantly identifiable, distinct E/M service are provided on the same day, a different diagnosis is not required. 12

CMS Discarded Drug Policy 15

When a physician, hospital, or other provider or supplier must discard the remainder of a single-use vial or other single-use package after administering a dose/quantity of the drug or biologic to a Medicare patient, the program provides payment for the amount of drug or biologic discarded as well as the dose administered, up to the amount of the drug or biologic as indicated on the vial or package label.

Medicare contractors require the modifier JW to identify unused drugs or biologics from single-use vials or single-use packages that are appropriately discarded. This modifier, billed on a separate claim line, supports payment for the amount of discarded drug or biologic.

For example, a single-use vial that is labeled to contain 100 units of a drug has 95 units administered to the patient and 5 units discarded. The 95-unit dose is billed on one line, while the discarded 5 units is billed on another line accompanied by the JW modifier. Both line items will be processed for payment.

Providers must record the discarded amounts of drugs and biologics in the patient’s medical record.

JW Modifier Summary

• Payment for discarded amounts of drug/biologic applies only to single-use vials or packages
• Multiuse vials are not subject to payment for discarded amounts
• Discarded amounts of drugs/biologics must be recorded in the patient’s medical record
• Medicare contractors require the JW modifier; other payer policies may vary

Drugs Supplied at No Cost to the Provider

Under certain circumstances, qualified patients may acquire donated or no-cost drugs, or drugs may be covered under a pharmacy benefit and delivered to the administering provider (“white bagging”). When the drug is supplied by a third party, at no cost to the provider, it should NOT be billed to Medicare or any other payer. However, the administration of the drug, regardless of the source, is a service that represents an expense to the physician. Therefore, administration of the drug is payable if the drug would have been covered if the physician purchased it. When reporting drug administration services for free-of-charge drugs, it may be necessary to include drug information on the claim and enter “0.01” charges. 17

Payer policies may vary.

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
SAMPLE CLAIMS FORMS

Physician Office Claims (CMS-1500)

The Form CMS-1500 is the basic form prescribed by CMS for the Medicare and Medicaid programs for claims from suppliers and non-institutional providers who qualify for a waiver from the Administrative Simplification Compliance Act (ASCA) requirement for electronic submission of claims. It has also been adopted by the TRICARE Program. For detailed guidance on completing the CMS-1500 items, please see the Medicare Claims Processing Manual, Pub. 100-04, Chapter 26, available at:


The 837P (Professional) is the standard format used by HCPs and suppliers to transmit healthcare claims electronically. The American National Standards Institute (ANSI) Accredited Standards Committee (ASC) X12N 837P (Professional) Version 5010A1 is the current electronic claim version. Data elements in the CMS uniform electronic billing specifications are consistent with the hard copy data set to the extent that one processing system can handle both. Medicare Administrative Contractors may include a crosswalk between the ASC X12N 837P and the CMS-1500 on their websites.

Hospital Outpatient Claims (CMS-1450)

The Form CMS-1450, also known as the UB-04, is a uniform institutional provider bill suitable for use in billing multiple third-party payers. It is the basic form prescribed by CMS for the Medicare and Medicaid programs for claims from hospitals, including hospital outpatient departments (HOPDs). Because it serves many payers, a particular payer may not need some data elements. For detailed guidance on completing the CMS-1450 items, please see the Medicare Claims Processing Manual, Pub. 100-04, Chapter 25, available at:


The 837I (Institutional) is the standard format used by institutional providers to transmit healthcare claims electronically. The ANSI ASC X12N 837I (Institutional) Version 5010A2 is the current electronic claim version. Data elements in the uniform electronic billing specifications are consistent with the hard copy data set to the extent that one processing system can handle both. Medicare Administrative Contractors may include a crosswalk between the ASC X12N 837I and the CMS-1450 on their websites.

For more information on electronic claims, please see the CMS website at:


Please see Important Safety Information for REMICADE® and Infliximab
on pages 22 and 23.

Back to Table of Contents.
Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
### 2021 Physician Office Sample Claim Form: CMS-1500

1. **Item 19**—Some payers may require additional information (e.g., a statement that the patient is on concomitant methotrexate) or additional codes such as the NDC. Payer requirements may vary.*

2. **Item 21**—Indicate diagnosis/diagnoses using appropriate ICD-10-CM codes. Use diagnosis codes to the highest level of specificity for the date of service and enter the diagnoses in priority order.

3. **Item 24D**—Indicate appropriate CPT® and HCPCS codes and modifiers if required.

#### REMICADE® or Infliximab

J1745 - Injection, infliximab, excludes biosimilar, 10 mg

If line item NDC information is required, it will be entered in the shaded portion of Item 24A. For example:

<table>
<thead>
<tr>
<th>Item</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>N457894003001 UN4</td>
<td>J1745</td>
</tr>
</tbody>
</table>

Payer requirements for NDC entries may vary.*

**Infusion Services**

96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour
96415 - Each additional hour

4. When it is necessary to discard the remainder of a single-use vial after administering a dose of drug/biologic to a Medicare patient, the program provides payment for the amount discarded as well as the dose administered. Medicare requires the modifier JW be appended to the discarded amount, billed on a separate line from the administered dose. Other payer policies may vary.*

5. **Item 24E**—Refer to the diagnosis for this service (see Item 21). Enter only one diagnosis pointer.

6. **Item 24G**—Enter the number of HCPCS units: 10 mg = 1 unit (100-mg vial = 10 units).

---

*For information and assistance, please contact Janssen CarePath at 877-CarePath (877-227-3728) or visit JanssenCarePath.com/hcp/remicade.

---

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
SAMPLE CLAIMS FORMS (cont’d)

2021 HOPD Sample Claim Form: CMS-1450 (UB-04)

1. **Locator Box 42**—List revenue codes in ascending order.

2. **Locator Box 43**—Enter narrative description for corresponding revenue code (e.g., IV therapy, drug). If line item NDC information is required, it will be entered in the unshaded portions of Locator Box 43. Payer requirements for NDC entries may vary.*

3. **Locator Box 44**—Indicate appropriate CPT® and HCPCS codes and modifiers as required by payer.

**REMICADE® or Infliximab**

- **J1745** - Injection, infliximab, excludes biosimilar, 10 mg

**Infusion Services**

- **96413** - Chemotherapy administration, intravenous infusion technique; up to 1 hour
- **96415** - Each additional hour

**Modifiers**

*PO or PN modifiers must be reported by all off-campus HOPDs. The PO modifier is to be reported with every HCPCS code for all items and services furnished in an *excepted*, off-campus PBD of a hospital. The PN modifier is to be reported on each claim line for all items and services furnished in a *non-excepted*, off-campus PBD of a hospital.*

*JG and TB modifiers must be reported for all 340B-acquired drugs. Providers who are not excepted from the 340B payment policy will report modifier JG. Providers who are excepted from the 340B payment policy will report informational modifier TB.*

4. **Locator Box 46**—Enter the number of HCPCS units: 10 mg = 1 unit (100-mg vial = 10 units).

5. **Locator Box 47**—Indicate total charges.

6. **Locator Box 47**—Indicate diagnosis using appropriate ICD-10-CM codes. Use diagnosis codes to the highest level of specificity for the date of service and enter the diagnoses in priority order.

*For information and assistance, please contact Janssen CarePath at 877-CarePath (877-227-3728) or visit JanssenCarePath.com/hcp/remicade.

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
COVERAGE CONSIDERATIONS

Factors That Influence Coverage

Third-party payers (eg, commercial insurers, Medicare, Medicaid) will generally cover parenteral drugs for their approved U.S. Food and Drug Administration indications and the associated professional administration services. However, benefits may vary depending upon the payer and the specific plan (“insurance product”) in which a patient is enrolled.

Medical Necessity

When third-party payers review infusible drug claims, they will first determine if the type of service provided is covered under their policies. Next, payers will look for evidence supporting the medical necessity of the therapy. This evidence may include:

• Information about the patient’s medical condition and history
• A physician’s statement or Letter of Medical Necessity
• Supporting literature (eg, peer-reviewed studies and compendia monographs)
• Full Prescribing Information
• Availability of other treatment alternatives

Medical necessity refers to a decision by a health plan that a treatment, test, or procedure is necessary for health or to treat a diagnosed medical problem. Health insurance companies provide coverage only for health-related services that they define or determine to be medically necessary. Medicare National Coverage Determinations (NCDs) and Medicare Administrative Contractors (MACs) Local Coverage Determinations (LCDs) define medical necessity requirements for Medicare coverage. These documents contain guidance on covered diagnoses, required documentation, and limitations of coverage for specific services in accordance with medical necessity.

Administrative Considerations

Other considerations may be involved in a payer’s decision to cover a product or service:

• Does the payer cover the therapy only when provided through a specific treatment site?

Payers may have site-specific coverage rules that restrict provision of infused therapies. For example, currently Medicare does not cover infusions when they are billed by Medicare-certified ambulatory surgery centers. Payers also may restrict coverage for certain infused drugs in the home or hospital outpatient setting.

• Is the billing provider a “participating” member of, or “in-network” provider for, that particular plan?

Payers contract with providers to deliver services to the plan’s members. Providers are thus “participating” or within that plan’s network, requiring them to abide by the contract charge structure when providing care for that plan’s members.

• Is the plan willing to grant in-network status when a service is otherwise out of network?

In some cases (eg, when there are no available in-network providers), health plans may grant in-network status for a provider and related services. In such cases, the provider accepts the in-network rate and the patient will be able to access in-network cost-sharing. It may be helpful to contact a payer to ask for a service to be converted to in-network status.

• If required by the plan, has the appropriate referral or prior authorization (PA) been obtained?

Many plans require that nonemergency services be preapproved or that a primary care physician make the referral for specialty care. Failing to obtain appropriate referrals or preauthorization can result in nonpayment by the plan.

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.

Back to Table of Contents.
Access support to help navigate payer processes

Janssen CarePath helps verify insurance coverage for your patients taking REMICADE® or Infliximab and provides reimbursement information.

Our digital resources available at JanssenCarePathPortal.com include:

- eBenefits investigations
- ePrior authorization support and status monitoring
  - Payer-specific Prior Authorization (PA) forms delivered in Portal
- eCreation of medical necessity and exceptions letters
- eRequest for exceptions and appeals information
- Online coding and billing information
- Online Secure Messaging to ask a question, request a status update, or send missing information related to an existing case
- Triage to specialty pharmacy providers, if needed

Learn more

Affordability support to help your patients start and stay on the Janssen treatment you prescribe

Janssen CarePath can help you find out what affordability assistance may be available for your patients taking REMICADE® or Infliximab:

Support for patients using commercial or private insurance:

- **Janssen CarePath Savings Program**
  - allows eligible patients to save on their out-of-pocket medication costs.
  - Eligible patients pay $5 for each infusion, with a $20,000 maximum program benefit per calendar year.
  - Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications.
  - Terms expire at the end of each calendar year and may change. There is no income requirement. For medication costs only; program does not cover cost to give patients their infusion.
  - See full eligibility requirements at JanssenCarePath.com.

  Support for patients using government-funded healthcare programs or patients without insurance coverage:

  - Janssen CarePath can help identify independent foundations that may be able to assist your patients*
  - Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728) or direct patients to visit JanssenCarePath.com.

Learn more

Treatment support to help your patients get informed and stay on prescribed treatment

Janssen CarePath provides additional support to your patients taking REMICADE® or Infliximab, including:

- Care coordination with treatment provider or pharmacy
- Treatment demonstration videos
- Nurse Support to answer patients’ questions†
- Personalized treatment reminders
- Patient education and tools
- Infusion site locator at 2infuse.com

Learn more

*Independent co-pay assistance foundations have their own rules for eligibility. We have no control over these independent foundations and can only refer your patients to a foundation that supports their disease state. We do not endorse any particular foundation.

†Nurse support is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient’s understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient’s doctor or nurse, provide case management services, or serve as a reason to prescribe.
IMPORTANT SAFETY INFORMATION

SERIOUS INFECTIONS
Patients treated with either REMICADE® or Infliximab are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue either REMICADE® or Infliximab if a patient develops a serious infection or sepsis.

Reported infections include:
- Active tuberculosis (TB), including reactivation of latent TB. Patients should be tested for latent TB before and during treatment with either REMICADE® or Infliximab. Treatment for latent infection should be initiated before treatment with either REMICADE® or Infliximab.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis, and cryptococcosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella, Listeria, and Salmonella.

The risks and benefits of treatment with either REMICADE® or Infliximab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with either REMICADE® or Infliximab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy, who are on treatment for latent TB, or who were previously treated for TB infection.

Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with co-morbid conditions and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with either REMICADE® or Infliximab included pneumonia, cellulitis, abscess, and skin ulceration.

MALIGNANCIES
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including either REMICADE® or Infliximab. Approximately half of these cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.

Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including either REMICADE® or Infliximab. These cases have had a very aggressive disease course and have been fatal. The majority of reported REMICADE® and Infliximab cases have occurred in patients with Crohn’s disease or ulcerative colitis and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with either REMICADE® or Infliximab at or prior to diagnosis. Carefully assess the risks and benefits of treatment with either REMICADE® or Infliximab, especially in these patient types.

In clinical trials of all TNF blockers, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn’s disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF blockers, including either REMICADE® or Infliximab, more cases of other malignancies were observed compared with controls. The rate of these malignancies among patients treated with either REMICADE® or Infliximab was similar to that expected in the general population whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. As the potential role of TNF blockers in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapies, including either REMICADE® or Infliximab. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. A population-based retrospective cohort study found a 2- to 3-fold increase in the incidence of invasive cervical cancer in women with rheumatoid arthritis treated with either REMICADE® or Infliximab compared to biologics-naïve patients or the general population, particularly those over 60 years of age. A causal relationship between either REMICADE® or Infliximab and cervical cancer cannot be excluded. Periodic screening should continue in women treated with either REMICADE® or Infliximab.

CONTRAINDICATIONS
The use of either REMICADE® or Infliximab at doses ≥5 mg/kg is contraindicated in patients with moderate or severe heart failure. REMICADE® and Infliximab are contraindicated in patients with a previous severe hypersensitivity reaction to infliximab or any of the inactive ingredients of REMICADE® and Infliximab or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness).

HEPATITIS B REACTIVATION
TNF blockers, including REMICADE® and Infliximab, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating either REMICADE® or Infliximab. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing either REMICADE® or Infliximab for patients identified as carriers of HBV and monitor closely for active HBV infection.
HEPATITIS B REACTIVATION (CONT’D)
during and following termination of therapy with either REMICADE® or Infliximab. Discontinue either REMICADE® or Infliximab in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of either REMICADE® or Infliximab and monitor patients closely.

HEPATOTOXICITY
Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported in patients receiving either REMICADE® or Infliximab postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, either REMICADE® or Infliximab should be discontinued, and a thorough investigation of the abnormality should be undertaken.

HEART FAILURE
In a randomized, placebo-controlled study in patients with moderate or severe heart failure (NYHA Functional Class III/IV), higher mortality rates and a higher risk of hospitalization were observed at Week 28 at a dose of 10 mg/kg and higher rates of cardiovascular events were observed at both 5 mg/kg and 10 mg/kg. There have been postmarketing reports of new onset and worsening heart failure, with and without identifiable precipitating factors. Patients with moderate or severe heart failure taking either REMICADE® or Infliximab (≤5 mg/kg) or patients with mild heart failure should be closely monitored and treatment should be discontinued if new or worsening symptoms appear.

HEMATOLOGIC EVENTS
Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported. The causal relationship to REMICADE® and Infliximab therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of either REMICADE® or Infliximab in patients who develop significant hematologic abnormalities.

HYPERSENSITIVITY
REMICADE® and Infliximab have been associated with hypersensitivity reactions that differ in their time of onset. Anaphylaxis, acute urticaria, dyspnea, and hypotension have occurred in association with infusions of either REMICADE® or Infliximab. Medications for the treatment of hypersensitivity reactions should be available.

CARDIOVASCULAR AND CEREBROVASCULAR REACTIONS DURING AND AFTER INFUSION
Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of either REMICADE® or Infliximab infusions. Cases of transient visual loss have been reported during or within 2 hours of either REMICADE® or Infliximab infusions. Monitor patients during infusion and if a serious reaction occurs, discontinue infusion. Manage reactions according to signs and symptoms.

NEUROLOGIC EVENTS
TNF blockers, including REMICADE® and Infliximab, have been associated with CNS manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome. Exercise caution when considering either REMICADE® or Infliximab in patients with these disorders and consider discontinuation if these disorders develop.

CONCURRENT ADMINISTRATION WITH OTHER BIOLOGICS
Concurrent use of either REMICADE® or Infliximab with anakinra, abatacept, tocilizumab, or other biologics used to treat the same conditions as REMICADE® and Infliximab is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.

AUTOIMMUNITY
Treatment with either REMICADE® or Infliximab may result in the formation of autoantibodies and in the development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

VACCINATIONS AND USE OF LIVE VACCINES/ THERAPEUTIC INFECTIOUS AGENTS
Prior to initiating either REMICADE® or Infliximab, update vaccinations in accordance with current vaccination guidelines. Live vaccines or therapeutic infectious agents should not be given with either REMICADE® or Infliximab due to the possibility of clinical infections, including disseminated infections. At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to either REMICADE® or Infliximab.

ADVERSE REACTIONS
In clinical trials, the most common adverse reactions occurring in >10% of REMICADE®- and Infliximab-treated patients included infections (eg, upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.

For more information, please see the full Prescribing Information, including Boxed Warning and Medication Guide for REMICADE® and full Prescribing Information, including Boxed Warning and Medication Guide for Infliximab. Provide the Medication Guides to your patients and encourage discussion.

Patient insurance benefits investigation and other Janssen CarePath program offerings are provided by third-party service providers for Janssen CarePath, under contract with Johnson & Johnson Health Care Systems Inc. on behalf of Janssen Pharmaceuticals, Inc., Janssen Biotech, Inc., and Janssen Products, LP (Janssen). Janssen CarePath is not available to patients participating in the Patient Assistance Program offered by Johnson & Johnson Patient Assistance Foundation. The availability of information and assistance may vary based on the Janssen medication, geography, and other program differences. Janssen CarePath assists healthcare providers (HCPs) in the determination of whether treatment could be covered by the applicable third-party payer based on coverage guidelines provided by the payer, and patient information provided by the HCP under appropriate authorization following the provider’s exclusive determination of medical necessity. This information and assistance are made available as a convenience to patients, and there is no requirement that patients or HCPs use any Janssen product in exchange for this information or assistance. Janssen assumes no responsibility for and does not guarantee the quality, scope, or availability of the information and assistance provided. The third-party service providers, not Janssen, are responsible for the information and assistance provided under this program. Each HCP and patient is responsible for verifying or confirming any information provided. All claims and other submissions to payers should be in compliance with all applicable requirements.

Please see Important Safety Information for REMICADE® and Infliximab on pages 22 and 23.


Back to Table of Contents.